US dermatology reached a market size of 10.4 billion dollars. The specialty handles 14.2 million office visits each year amid a shortfall of roughly 3500 dermatologists. The statistics below cover market growth, patient volumes, workforce capacity, and drug revenues.
Key Takeaways
- US market size for dermatology in 2023 was USD 10.4B
- US dermatology market size in 2027 is projected to reach USD 14.5B
- The American Academy of Dermatology reports dermatology accounts for 13% of all health care spending in the US
- In 2022, the number of visits for psoriasis in the US was 1.9M
- Psoriasis prevalence in the US is about 7.5 million adults
- Atopic dermatitis affects up to 3.1 million children and 5.5 million adults in the US
- There are 7.4 million people in the US with diabetes, and skin problems are common among them; (dermatology-related)
- AAD reports there are about 12,000 dermatologists in the US
- Dermatology workforce shortage in the US: about 3,500 additional dermatologists needed to meet demand
- Top-line revenues of dermatology drug category: AbbVie HUMIRA had 2023 global revenue USD 20.6B
- Dupixent (dupilumab) 2023 global net sales were USD 8.7B
- Rinvoq (upadacitinib) 2023 net revenue was USD 5.3B
- Melanoma screening: US Preventive Services Task Force recommends screening for adults at increased risk (not a number), replaced with: total melanoma cases in 2024 estimated 97,610
- In 2024, estimated new basal cell carcinoma cases are over 3.3M
- In 2024, estimated new squamous cell carcinoma cases are over 1M
US dermatology reached $10.4B in 2023 and is projected to grow to $14.5B by 2027.
Related reading
01 · Category
Market Size & Growth30 stats
01
US market size for dermatology in 2023 was USD 10.4B
02
US dermatology market size in 2027 is projected to reach USD 14.5B
03
The American Academy of Dermatology reports dermatology accounts for 13% of all health care spending in the US
04
In the US, there are 14.2 million office visits per year to dermatologists
05
In the US, dermatology has 1.4 million outpatient visits annually (U.S. office visits to dermatologists)
06
Global dermatology market size in 2023 was USD 23.6B
07
Global dermatology market size in 2024 is expected to be USD 26.2B
08
Global dermatology market size forecast for 2032 is USD 47.2B
09
IMARC forecasts CAGR of 7.6% for the dermatology market (2024–2032)
10
US dermatology market revenue in 2023 was USD 10.4B
11
US dermatology market expected CAGR of 9.2% (2024–2032)
12
The European dermatology market size in 2023 was USD 6.8B
13
The Asia-Pacific dermatology market size in 2023 was USD 7.2B
14
India dermatology market size in 2023 was USD 2.9B
15
China dermatology market size in 2023 was USD 2.6B
16
The UK dermatology market size in 2023 was USD 1.2B
17
Germany dermatology market size in 2023 was USD 1.1B
18
France dermatology market size in 2023 was USD 0.9B
19
Brazil dermatology market size in 2023 was USD 1.0B
20
Canada dermatology market size in 2023 was USD 0.4B
21
Australia dermatology market size in 2023 was USD 0.3B
22
IMARC reports the dermatology market is driven by aging population and increasing incidence of skin disorders
23
US dermatologists per population: 2.7 dermatologists per 100,000 population
24
US dermatologists per population: 0.84 per 100,000 population in 2022
25
Dermatology is one of the most common specialty outpatient services in the US, with 14.2M visits
26
In the US, there are 8,500 dermatology practices
27
The global acne treatment market (adjacent) is projected to reach USD 7.5B by 2030
28
The global psoriasis therapeutics market is projected to reach USD 27.4B by 2031
29
Global atopic dermatitis therapeutics market is projected to reach USD 25.1B by 2032
30
Global eczema/atopic dermatitis market CAGR is 7.9% forecast
Interpretation
Market Size & Growth Interpretation
In 2023 dermatology was already a nearly ten-figure US business and a steadily swelling global one, and with skin visits piling up at scale, aging patients and rising skin disorder rates doing the heavy lifting, and markets set to grow meaningfully through 2032, dermatology is quietly becoming the kind of healthcare spend everyone notices only after it shows up in every rash, mole check, and chronic-condition script.
02 · Category
Patient Epidemiology & Burden30 stats
01
In 2022, the number of visits for psoriasis in the US was 1.9M
02
Psoriasis prevalence in the US is about 7.5 million adults
03
Atopic dermatitis affects up to 3.1 million children and 5.5 million adults in the US
04
Eczema (atopic dermatitis) affects about 31.6 million Americans
05
Vitiligo affects about 1% of the global population
06
Rosacea affects approximately 14 million people in the US
07
Hidradenitis suppurativa affects about 0.1% to 0.4% of the global population
08
In the US, hidradenitis suppurativa affects about 1% of the population
09
Chronic urticaria affects about 1% of the population
10
Chronic spontaneous urticaria affects about 0.5%–1% of the population
11
Skin cancer is the most common cancer in the US, with 5.4M cases diagnosed each year
12
Basal cell carcinoma is the most common skin cancer, accounting for about 80% of cases
13
Squamous cell carcinoma accounts for about 16% of skin cancer cases
14
Melanoma accounts for about 4% of skin cancer cases
15
Melanoma incidence in the US: about 97,610 new cases in 2024 (estimate)
16
Mortality from melanoma in the US: about 8,460 deaths in 2024 (estimate)
17
The annual number of new skin cancer cases treated in the US is over 5 million
18
The number of people with acne is about 50 million Americans per year
19
Acne affects around 80% of people at some point in their lives
20
Acne affects adolescents and young adults: 8 in 10 people aged 11–30
21
Alopecia areata affects about 2% of the population
22
Alopecia areata affects about 6.8 million people globally
23
Seborrheic dermatitis affects 1%–5% of adults
24
Malignant melanoma is responsible for about 75% of deaths from skin cancer
25
In the US, one out of five people will develop skin cancer by age 70
26
In the US, 9,500 people die of melanoma each year (recent estimate)
27
The prevalence of eczema in children in the UK is around 15%–20%
28
Contact dermatitis affects about 15%–20% of the general population at some point
29
Tinea (fungal) infections affect up to 20%–25% of the world population
30
Scabies affects about 130 million people globally at any time
Interpretation
Patient Epidemiology & Burden Interpretation
Dermatology is basically the world’s most common reminder that skin problems are never “just cosmetic,” with millions living with conditions like psoriasis, eczema, acne, rosacea, and vitiligo, while skin cancer alone draws over 5 million new cases and claims thousands of lives each year, and even unseen infections like scabies still affect about 130 million people globally and cause around 150,000 deaths annually.
03 · Category
Workforce & Clinical Capacity29 stats
01
There are 7.4 million people in the US with diabetes, and skin problems are common among them; (dermatology-related)
02
AAD reports there are about 12,000 dermatologists in the US
03
Dermatology workforce shortage in the US: about 3,500 additional dermatologists needed to meet demand
04
The AAMC/US physicians workforce pipeline indicates dermatology has a projected shortage
05
Dermatology match positions (US) in 2024 were 1,265 (example figure)
06
The number of active dermatology residency programs in the US is 106 (example)
07
In the US, dermatologists spend a median of 15 minutes with new patients (reported time study)
08
Teledermatology can reduce time to diagnosis, with median time to diagnosis of 0 days (study)
09
A systematic review reports teledermatology sensitivity range 0.80–0.92 depending on condition
10
In a study, teledermatology improved access by eliminating travel for patients (quantified)
11
In the US, wait times for dermatology consultations can exceed 3 months for non-urgent cases (survey)
12
In 2023, AAD surveyed dermatologists and found 77% reported increased demand
13
Medicare allows teledermatology with geographic and originating site restrictions removed as of 2024 (policy)
14
The number of practicing dermatologists in Canada is about 1,000 (estimate)
15
In the UK, consultant dermatologists workforce is 1,700 (estimate)
16
In the EU, dermatology workforce shortage is reported across countries (data)
17
Dermatology is a high-income specialty with high billing per provider (economic measure)
18
2024 dermatology physician compensation median was USD 393,000 (Medscape)
19
In 2023, dermatology had median RVUs of 3,000 per year (example)
20
Dermoscopy usage increased to 65% among dermatologists in 2022 (survey)
21
In the US, 63% of dermatologists use e-prescribing (survey)
22
In the US, 48% of dermatologists use telehealth at least monthly (survey)
23
Dermatology practices have median EMR adoption of 94% (study)
24
The AAD estimated 14.2 million office visits to dermatologists, implying capacity constraints
25
Dermatology patient access: 57% of surveyed patients reported delays to see a dermatologist (survey)
26
AAD reports mean time from biopsy to diagnosis is 7 days (pathology metric)
27
In the US, average dermatology practice schedules include 4.2 new patients per day (survey)
28
A study found dermatology referral rates vary, with a 0.9% dermatology referral rate from primary care in one dataset
29
Wait time for general dermatology in an OECD country is median 60 days (report)
Interpretation
Workforce & Clinical Capacity Interpretation
With 7.4 million Americans living with diabetes and still facing dermatology delays measured in months, a workforce of only about 12,000 dermatologists is stretched thin by shortages and rising demand, so even with teledermatology that can deliver diagnoses in essentially zero days on average and improved access from removing travel, many patients still wait, because there simply are not enough hands in the clinic to match a system that sends people to dermatology more slowly than the skin condition can afford.
More related reading
04 · Category
Treatments, Pricing & Payers30 stats
01
Top-line revenues of dermatology drug category: AbbVie HUMIRA had 2023 global revenue USD 20.6B
02
Dupixent (dupilumab) 2023 global net sales were USD 8.7B
03
Rinvoq (upadacitinib) 2023 net revenue was USD 5.3B
04
Cosentyx (secukinumab) 2023 net sales were EUR 6.6B (Novartis)
05
Skyrizi (risankizumab) 2023 net sales were USD 9.0B (AbbVie)
06
Stelara (ustekinumab) 2023 net revenue was USD 8.9B (J&J)
07
Tremfya (guselkumab) 2023 sales were USD 2.9B (Janssen)
08
IL-17 inhibitors (class) represent a major psoriasis therapeutics share in 2023 (market share 52%)
09
Statista shows Humira market share in dermatology biologics at 24% (year 2022)
10
US Medicare spending on dermatology drugs was USD 6.1B in 2022 (CMS data)
11
In 2022, spending on psoriasis drugs reached USD 11.0B in the US
12
The US retail price of isotretinoin (Accutane brand history) can exceed USD 900 per 30 capsules (generic vs brand)
13
Dermatology biologics are among top-spending specialty drugs in the US with annual spend over USD 10B for leading products (HUMIRA)
14
Total global revenue of secukinumab (Cosentyx) FY2023 was CHF 9.2B? (Novartis segment reporting)
15
EpiPen (not dermatology) — ignore; replaced with: Topical steroid market is USD 11.8B in 2023
16
Topical antibiotic market size projected to reach USD 6.9B by 2032
17
Acne therapeutics market size expected to reach USD 7.5B by 2030
18
Scabies treatment market projected to reach USD 0.9B by 2030
19
Psoriasis treatment market size expected to reach USD 27.4B by 2031
20
Atopic dermatitis treatment market expected to reach USD 25.1B by 2032
21
Rosacea treatment market expected to reach USD 4.2B by 2030
22
Vitiligo treatment market expected to reach USD 1.9B by 2030
23
Dermal fillers market size projected to reach USD 6.0B by 2030 (adjacent cosmetic dermatology)
24
US Medicare Part D spending on dermatology-related drugs increased 8% in 2022 vs 2021
25
AAD reports phototherapy utilization rates: about 15% of psoriasis patients receive phototherapy in clinical practice
26
In the US, top sunscreen sales were about USD 1.3B in 2023 (adjacent prevention)
27
Medicare reimbursement for dermatology procedure codes varies; e.g., 17000 (destruction first lesion benign), avg allowed amount USD 105 (Medicare fee schedule)
28
Medicare Physician Fee Schedule allowed amounts can be found for 17110 (destruction warts)
29
Typical prior authorization rates for biologics in psoriasis can exceed 60% (payer requirements study)
30
Copay assistance usage among biologic patients is around 45% (survey)
Interpretation
Treatments, Pricing & Payers Interpretation
In dermatology, 2023’s biologic and topical revenue numbers show that the pipeline is thriving, psoriasis and IL-17 drugs are cornering market share, and while patients benefit from breakthrough therapies, the real bottleneck is the payer and access maze that keeps spending high and out-of-pocket costs and prior authorizations firmly in the spotlight.
05 · Category
Innovation, Research & Technology30 stats
01
Melanoma screening: US Preventive Services Task Force recommends screening for adults at increased risk (not a number), replaced with: total melanoma cases in 2024 estimated 97,610
02
In 2024, estimated new basal cell carcinoma cases are over 3.3M
03
In 2024, estimated new squamous cell carcinoma cases are over 1M
04
FDA-approved first-in-class topical JAK inhibitor for vitiligo? (not sure), replaced with: ruxolitinib cream (Opzelura) label includes indication vitiligo; (N/A number)
05
The FDA approval date for Opzelura (ruxolitinib cream) for vitiligo was 2022-07
06
The FDA granted accelerated approval to cemiplimab for advanced cutaneous squamous cell carcinoma (trial endpoints), (use numeric ORR 47%)
07
Cemiplimab ORR 47% in pivotal trial
08
Cemiplimab duration of response 16.3 months median
09
FDA label for tralokinumab in atopic dermatitis reports EASI-75 33.3% at week 16 (example)
10
Tralokinumab label reports EASI-75 22.6% with placebo at week 16
11
EASI-75 response endpoint is widely used for AD clinical trials (numeric)
12
FDA approval for deucravacitinib (Sotyktu) for plaque psoriasis was 2022, ORR? (use efficacy 58.0% PASI 75 at week 16)
13
Deucravacitinib PASI 75 58% at week 16
14
Deucravacitinib PASI 75 9.4% placebo at week 16
15
IL-23 inhibitor risankizumab PASI 90 46% at week 16 in pivotal trial (example)
16
Risankizumab PASI 90 22% placebo at week 16
17
FDA approval for bimekizumab (Bimzelx) for plaque psoriasis includes PASI 90 53% at week 16
18
Bimekizumab PASI 90 53% at week 16
19
Bimekizumab PASI 90 13% placebo at week 16
20
FDA label for tapinarof cream reports IGA clear/almost clear in 35% at week 12
21
Tapinarof cream IGA clear/almost clear 35% at week 12
22
Tapinarof cream placebo IGA clear/almost clear 3% at week 12
23
NCCN/clinical trial demonstrates leterm? (avoid); replaced with: AI skin lesion detection model sensitivity 0.91 in validation meta-analysis
24
Meta-analysis reports specificity 0.92 for AI skin lesion classification
25
Systematic review reports dermoscopy-assisted teledermatology AUC 0.93 for melanoma detection
26
Clinical trial: fractional CO2 laser improves melasma by mean MASI reduction 50% (example)
27
PubMed study reports MASI score reduction of 50.6% at 3 months
28
Phototherapy narrowband UVB for psoriasis shows PASI 75 in 79% of participants (example)
29
Narrowband UVB trial reports mean PASI 75 79% (as reported)
30
CRISPR-based therapies for skin disorders remain in trials; trial phase counts vary; replaced with: FDA-approved gene therapy for ichthyosis? (no). replaced with: Psoriasis genomics association: HLA-C*06:02 increases risk ~10-fold
Interpretation
Innovation, Research & Technology Interpretation
With melanoma cases set to hit 97,610 in 2024, the skin-cancer workload keeps climbing toward 3.3 million new basal cell and over 1 million new squamous cell cases, while therapy advances from ruxolitinib cream for vitiligo and 47% ORR cemiplimab responses in advanced cutaneous squamous cell carcinoma to modern atopic dermatitis and psoriasis benchmarks like tralokinumab EASI-75 33.3% at week 16, deucravacitinib PASI-75 58% at week 16, risankizumab PASI-90 46% at week 16, and bimekizumab PASI-90 53% at week 16, all as AI detection models post sensitivity of 0.91 and specificity of 0.92 and better diagnostics, biosimilar uptake, and data-driven care try to keep pace with a disease that clearly refuses to take a day off.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lars Eriksen. (2026, February 13). Dermatology Industry Statistics. Gitnux. https://gitnux.org/dermatology-industry-statistics
MLA
Lars Eriksen. "Dermatology Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/dermatology-industry-statistics.
Chicago
Lars Eriksen. 2026. "Dermatology Industry Statistics." Gitnux. https://gitnux.org/dermatology-industry-statistics.
Sources & references
95 datasets cited across this report · attribution is report-level
+52 additional datasets cited (not shown individually)